Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman ...Middle East

REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline SAN FRANCISCO, Sept. 18, 2025 /PRNewswire/ -- On September 18, 2025, investors in Replimune Group, Inc. (NASDAQ: REPL) saw the price of their shares crater about 45% during intraday trading after the...

Hence then, the article about replimune repl shares tank 45 after company says no pathway identified for lead drug rp1 securities class action pending hagens berman was published today ( Thursday 18/09/2025 - 11:43 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman )

Also on site :

• Yeison Jiménez, Colombian Popular Music Star, Dies in Plane Crash at 34
• IND vs NZ Dream11 Prediction, Dream11 Playing XI, Today Match 1st, India vs New Zealand ODI series 2026
• OpenAI is reportedly asking contractors to upload real work from past jobs